Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome

NCT00199446 ↗

Phase 2 Completed 160 enrolled Kyowa Kirin, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) in patients with Restless Legs Syndrome.

Timeline

Start: 2005-07
Primary completion: 2006-08
Completion: 2006-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Istradefylline	Small molecule	40 mg	—

Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome

Summary

Timeline

Drugs

Indications